



AHCL/ SE/ 52/2023-24

February 09 2024

The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031	BSE Limited Department of Corporate Services 1 st Floor, P.J. Towers, Dalal Street, Mumbai 400 001
Symbol : AMRUTANJAN	Scrip Code: 590006

Dear Sir / Madam,

Sub: Outcome of the Board Meeting

In terms of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today (**February 09, 2024**) had inter-alia:

- (i) Approved the Un-audited Financial Results for the quarter ended December 31, 2023. The same along with the Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
- (ii) Declared Second Interim Dividend of Re.1/- per share for the financial year 2023-24 on the Equity Shares of the Company.

The Board Meeting commenced at 12.00 PM and concluded at 7. 15 P.M. Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For **Amrutanjan Health Care Limited**

(M Srinivasan)

Company Secretary & Compliance Officer

Encl:

1. Un-audited Standalone Financials Results for the quarter ended December 31, 2023
2. Limited Review Report

AMRUTANJAN HEALTH CARE LIMITED

CIN No : L24231TN1936PLC000017

Registered Office: No. 103 (Old No. 42-45), Luz Church Road

Mylapore, Chennai - 600 004

Statement of Unaudited Financial Results for the quarter and nine months ended 31 December 2023

Particulars	Amount in INR Lakhs					
	Quarter ended			Period ended		Year ended
	31 December 2023 (Unaudited)	30 September 2023 (Unaudited)	31 December 2022 (Unaudited)	31 December 2023 (Unaudited)	31 December 2022 (Unaudited)	31 March 2023 (Audited)
I Income						
Revenue from operations	11,699.37	9,931.16	9,764.55	29,416.83	27,931.91	37,963.60
Other income	376.39	394.75	367.75	1,139.77	972.23	1,454.17
Total income	12,075.76	10,325.91	10,132.30	30,556.60	28,904.14	39,417.77
II Expenses						
(a) Cost of materials consumed	2,874.62	2,327.71	2,754.73	7,440.38	8,308.10	10,517.33
(b) Purchases of stock-in-trade	2,715.61	2,916.88	1,612.67	7,525.80	5,155.73	7,853.27
(c) Changes in inventories of finished goods and stock-in-trade	66.99	(153.20)	(173.51)	(156.56)	(375.65)	(172.74)
(d) Employee benefits expense	1,204.98	1,181.02	1,201.93	3,522.97	3,644.06	4,881.02
(e) Advertisement and selling expenditure	1,362.91	1,705.24	1,988.02	3,722.11	4,544.63	5,258.16
(f) Finance cost	5.42	2.97	1.59	10.78	5.99	7.71
(g) Depreciation and amortisation expense	157.65	155.44	131.41	452.29	390.17	521.15
(h) Other expenses	1,316.94	1,269.31	1,165.12	3,804.68	3,513.67	5,187.33
Total expenses	9,705.12	9,405.37	8,681.97	26,322.45	25,186.70	34,053.23
III Profit before tax (I - II)	2,370.64	920.54	1,450.33	4,234.15	3,717.44	5,364.54
IV Tax expenses	625.69	235.62	379.26	1,102.79	1,003.47	1,381.05
V Profit after tax (III - IV)	1,744.95	684.92	1,071.07	3,131.36	2,713.97	3,983.49
VI Other comprehensive income						
Items that will not be reclassified subsequently to profit or loss						
Re-measurement gain/(loss) on defined benefit plans, net of taxes	(18.90)	10.75	(0.27)	(1.83)	(118.83)	(121.91)
Other comprehensive income/ (loss) for the period, net of taxes	(18.90)	10.75	(0.27)	(1.83)	(118.83)	(121.91)
VII Total comprehensive income for the period (V+VI)	1,726.05	695.67	1,070.80	3,129.53	2,595.14	3,861.58
Paid-up equity share capital (Face value Re. 1/- each)	289.11	289.11	292.31	289.11	292.31	292.31
Earnings per equity share for continuing operations						
Basic earnings per share (INR)	6.05	2.36	3.67	10.79	9.30	13.65
Diluted earnings per share (INR)	6.04	2.36	3.66	10.78	9.29	13.63
	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
See accompanying notes to unaudited financial results						




AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Notes:

- The above unaudited financial results for the quarter and nine months ended 31 December 2023 in respect of **Amrutanjan Health Care Limited** ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 9 February 2024. The above unaudited financial results have been subjected to limited review by the statutory auditors of the Company. The auditors have issued an unmodified review report.
- These unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Interim Dividend of Re. 1/- per share, aggregating to INR 289.11 Lakhs has been paid during the quarter ended 31 December 2023.
- During the financial year 2020-2021, Amrutanjan's Board of Directors had approved the Amrutanjan Health Care Limited Employee stock option scheme ('Scheme 2020') for the grant of stock options to the employees of the Company. The Compensation Committee administers the plan through a trust established specifically for this purpose, called Amrutanjan Health Care Limited ESOP Trust ('ESOP trust'). The assets and liabilities of the trust is accounted for as assets and liabilities of the Company on the basis that the trust is exclusively set up for the purpose of administering the ESOP plan of the Company.
- After obtaining the approval of the Board of Directors in their meeting held on 30 June 2023, the buy back of 320,000 Equity Shares of Rs 1/- each (Representing 1.09% of the total number of paid up equity shares of the company) from the shareholders of the company on proportionate basis, by way of tender offer route at a price of Rs 900/- per share for an aggregate amount of Rs 2,880.00 lakhs (9.80% of the paid up capital and free reserves), was initiated in accordance with the provisions of the Companies Act, 2013 and the SEBI (Buy Back of Securities) Regulation, 1998 and related taxes amounting to Rs 670.18 lakhs has been paid in accordance with the provisions of the Income Tax Act, 1961. The buy back procedures were completed on 03 August 2023.
- The unaudited financial results of the Company for the quarter and nine months ended 31 December 2023 has been filed with the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and are available in Company's website www.amrutanjan.com
- Segment reporting in the unaudited financial results:** Based on the 'management approach' as defined in Ind AS 108 'Operating Segments', the Chief Operating Decision Maker evaluates the Company's performance as OTC Products and Beverages.

Particulars	Amount in INR Lakhs					
	Quarter ended			Period ended		Year ended
	31 December 2023 (Unaudited)	30 September 2023 (Unaudited)	31 December 2022 (Unaudited)	31 December 2023 (Unaudited)	31 December 2022 (Unaudited)	31 March 2023 (Audited)
1 Segment revenue						
a OTC Products	11,179.26	9,408.19	9,351.22	27,202.12	26,015.95	34,511.23
b Beverages	518.32	484.32	365.23	2,131.58	1,761.91	3,246.33
c Others	1.79	38.65	48.10	83.13	154.05	206.04
Total	11,699.37	9,931.16	9,764.55	29,416.83	27,931.91	37,963.60
2 Segment results						
a OTC Products	2,093.99	755.59	1,368.12	3,517.78	3,515.12	4,880.03
b Beverages	53.42	(83.77)	(136.34)	(65.85)	(503.35)	(393.17)
c Others	(6.59)	(45.06)	(20.77)	(76.03)	(53.00)	(73.06)
Total	2,140.82	626.76	1,211.01	3,375.90	2,958.77	4,413.80
Less: Finance cost	5.42	2.97	1.59	10.78	5.99	7.71
Add: Other unallocable expenditure net of interest income	235.24	296.75	240.91	869.03	764.66	958.45
Total profit before tax	2,370.64	920.54	1,450.33	4,234.15	3,717.44	5,364.54
3 Segment assets						
a OTC Products	9,518.60	9,552.89	9,290.29	9,518.60	9,290.29	9,000.88
b Beverages	2,223.05	2,099.79	2,213.17	2,223.05	2,213.17	2,180.65
c Others	66.95	20.58	44.10	66.95	44.10	36.25
d Unallocated assets	24,252.29	23,832.15	24,203.19	24,252.29	24,203.19	24,991.55
Total	36,060.89	35,505.41	35,750.75	36,060.89	35,750.75	36,209.33
4 Segment liabilities						
a OTC Products	7,179.56	7,494.75	6,683.48	7,179.56	6,683.48	5,265.52
b Beverages	625.82	583.96	384.62	625.82	384.62	1,031.87
c Others	-	35.92	43.25	-	43.25	39.95
d Unallocated liabilities	616.57	1,190.48	547.48	616.57	547.48	794.80
Total	8,421.95	9,305.11	7,658.83	8,421.95	7,658.83	7,132.14
Total capital employed in the Company	27,638.94	26,200.30	28,091.92	27,638.94	28,091.92	29,077.19

For Amrutanjan Health Care Limited


S Sambhu Prasad
 Chairman & Managing Director
 DIN: 00015729

Date: 9 February 2024
 Place: Chennai

B S R & Co. LLP

Chartered Accountants

KRM Tower, 1st and 2nd Floors
No. 1, Harrington Road, Chetpet
Chennai – 600 031, India
Telephone: +91 44 4608 3100
Fax: +91 44 4608 3199

Limited Review Report on unaudited financial results of Amrutanjan Health Care Limited for the quarter ended 31 December 2023 and year to date results for the period from 1 April 2023 to 31 December 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Amrutanjan Health Care Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Amrutanjan Health Care Limited** (hereinafter referred to as "the Company") for the quarter ended 31 December 2023 and year to date results for the period from 1 April 2023 to 31 December 2023 ("the Statement") (in which are included unaudited interim financial results of Amrutanjan Health Care Limited ESOP Trust ("ESOP Trust")).
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Statement includes the unaudited interim financial results of ESOP Trust which has not been reviewed, whose unaudited interim financial results reflect total assets (before consolidation adjustments) of INR 474.96 Lakhs as at 31 December 2023, total revenues (before consolidation adjustments) of INR 1.69 Lakhs and total net profit after tax (before consolidation adjustments) of INR 1.69 Lakhs for the quarter ended 31 December 2023 and for the period from 1 April 2023 to 31 December 2023 respectively, as considered in the Statement. According to the information and explanations given to us by the management, these unaudited interim financials results are not material to the Company.

Our conclusion is not modified in respect of this matter.

for **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.: 101248W/W-100022



R Kalyana Sundara Rajan
Partner

Membership No.: 221822
UDIN: 24221822BKHBFF4683

Chennai
09 February 2024